Novartis AG has described peptide-drug conjugates comprising cyclic peptides targeting HER2 (erbB2) covalently linked to a radiolabeled metal chelator through a linker reported to be useful for diagnosis and treatment of cancer.

Pfizer Inc. has divulged gastric inhibitory polypeptide receptor (GIPR) antagonists reported to be useful for the treatment of type 2 diabetes and obesity.

Abbvie Inc. has identified lysophosphatidic acid receptor 1 (LPAR1; EDG2) antagonists reported to be useful for the treatment of fibrosis and inflammatory disorders.

Nanjing Zaiming Pharmaceutical Co. Ltd. has synthesized Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.

Shouyao Holdings (Beijing) Co. Ltd. has disclosed mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors reported to be useful for the treatment of cancer, rheumatoid arthritis, multiple sclerosis, psoriasis, Sjögren’s syndrome, systemic lupus erythematosus, erythema and vasculitis.

Suzhou Junjian Yifang Biopharmaceutical Co. Ltd. has described pyrimido[6,1-a]isoquinolin-4-one derivatives acting as dual phosphodiesterase PDE3 and PDE4 inhibitors reported to be useful for the treatment of asthma and chronic obstructive pulmonary disease.

Hangzhou Synrx Therapeutics Technology Co. Ltd. has divulged crystalline salts of DNA polymerase θ (POLθ) inhibitors reported to be useful for the treatment of cancer.

Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has identified fused bicyclic compounds reported to be useful for the treatment of cancer.

3H Pharmaceuticals Co. Ltd. has synthesized Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.

Innovstone Therapeutics Ltd. has disclosed integrin αLβ2 (LFA-1)/ICAM-1 interaction inhibitors and/or RASP-trapping agents reported to be useful for the treatment of dry eye syndrome.